C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and may be life-threatening. Prophylaxis and therapy of events has changed since our first Canadian Consensus Conference on the diagnosis, therapy and management of HAE. We have formed the Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'Angioédème Héréditaire (RCAH) - http://www.haecanada.com to advance care of patients with this disorder in Canada. We here present a review of management of HAE in Canada.
CITATION STYLE
Bowen, T., Brosz, J., Brosz, K., Hebert, J., & Ritchie, B. (2010). Management of hereditary angioedema: 2010 Canadian approach. Allergy, Asthma & Clinical Immunology, 6(1). https://doi.org/10.1186/1710-1492-6-20
Mendeley helps you to discover research relevant for your work.